KRAS and neoplasm: In addition, there was no difference in the levels of sXBP1 transcripts according to the mutational status of validated oncogenic drivers in the tumor sample (KRAS and EGFR), potential oncogenic drivers (STK11 and PI3KCA) and other mutated genes, including P53 (Fig. 2B–F).